Clinical trials: Chimerism, active
Acute Lymphocytic Leukemia
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side…
- Trial name
- NCT03104491
- Testing
- Inotuzumab Ozogamicin
- Where
- 7 sites in United States
- Volunteers
- 44 people
- Sponsor
- Leland Metheny
Renal Transplant Rejection, Tolerance
Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor
The purpose of this study is to find out if an investigational treatment will allow kidney transplant recipients to better accept their new kidney and stop immunosuppressive medicines.
- Conditions
- Renal Transplant Rejection, Tolerance, Kidney Transplant
- Trial name
- NCT03707262
- Testing
- Donor CD34+ and CD3+ cells
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jeffrey Veale, MD
Kidney Failure, Transplant Recipient (Kidney)
Tolerance Through Mixed Chimerism (Sip-Tego)
This is an open-label, single-institution study to assess the safety and the efficacy of the Sip-Tego regimen for the induction of donor-specific immunologic unresponsiveness to a renal allograft.
- Conditions
- Kidney Failure, Transplant Recipient (Kidney), Transplant Tolerance, Immunosuppresion
- Trial name
- NCT06972069
- Testing
- Combined Kidney/Bone Marrow Transplant, Donation of Kidney / Bone Marrow, Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Tatsuo Kawai, MD, PhD
Liver Transplantation, Liver Transplantation in Long-term
Immunosuppressant Withdrawal Based on Parenchymal Chimerism in the Liver Transplantation
The goal of this clinical trial is to learn whether liver parenchyma chimerism can represent a chievement of operational tolerance in liver transplantation recipients.
- Trial name
- NCT07735650
- Testing
- liver biopsy, Immunosuppression withdrawal, Immunosuppression minimization
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Chang Gung Memorial Hospital
Recurrent Severe Aplastic Anemia, Refractory Severe Aplastic Anemia
A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia
This phase I trial evaluates the safety and feasibility of using a reduced-intensity regimen of cyclophosphamide, pentostatin, and anti-thymocyte globulin prior to a CD4+ T-cell depleted haploidentical hematopoietic cell…
- Trial name
- NCT05757310
- Testing
- Anti-Thymocyte Globulin, Biospecimen Collection, Bone Marrow Aspirate
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Renal Failure
Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH
The goal is to investigate the safety of the conditioning regimen, and its ability to induce donor/recipient lymphohematopoietic chimerism without Chimerism Transition Syndrome (CTS), which may result in donor-specific…
- Trial name
- NCT04540380
- Testing
- Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab, Combined bone marrow and kidney transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Sickle Cell Anemia, Beta Thalassemia
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia
Background: Sickle cell disease (SCD) is an inherited disorder of the blood. It can damage a person s organs and cause serious illness and death. A blood stem cell transplant is the only potential cure for SCD.
- Trial name
- NCT05357482
- Testing
- TBI, Hydroxyurea, briquilimab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Leukemia, Lymphoma
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Background: After an allogeneic hematopoietic stem cell transplant (HSCT), the donor genome is found in the recipient s circulation and tissues.
- Conditions
- Leukemia, Lymphoma, Hematologic Malignancy
- Trial name
- NCT06856226
- Testing
- Arm 1
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Sickle Cell Disease, Sickle Cell Disorder
A Blood Stem Cell Transplant for Sickle Cell Disease
Blood stem cells can produce red blood cells (which carry oxygen), white blood cells of the immune system (which fight infections) and platelets (which help the blood clot).
- Conditions
- Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies, Thalassemia
- Trial name
- NCT03249831
- Testing
- Cyclophosphamide, Pentostatin, Rabbit anti-thymocyte globulin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Liver Transplantation, Immune Tolerance
Immune Tolerance Induction After Liver Transplantation
This clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery.
- Conditions
- Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects, Graft Survival
- Trial name
- iTILT (NCT07269041)
- Testing
- Donor Hematopoietic Stem and Progenitor Cell Infusion
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, Los Angeles
Intestinal Transplantation
Using T-Cell Alloreactivity and Chimerism to Guide Immunosuppression Minimization in Intestinal Transplantation
The purpose of this study is to investigate the safety and feasibility of giving intestinal transplant patients CD34+ stem cells (the cells that make all the types of blood cells) obtained from their organ donor's bone marrow.
- Trial name
- NCT04804891
- Testing
- Cell Therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Myeloid Chimerism
Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels
Background: Sickle cell disease can often be treated with blood stem cell transplants. But for some people the disease returns. This study will give a second transplant to people whose disease has returned but still have some…
- Trial name
- NCT04008368
- Testing
- CliniMACS CD34 Reagent
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myeloid Malignancy
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor…
- Trial name
- NCT03850418
- Testing
- azacitidine
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Henry Ford Health System
Sickle Cell Disease, Beta-thalassemia
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions.
- Trial name
- NCT07599176
- Testing
- Total Body Irradiation, Alemtuzumab, Abatacept
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Disease
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
Background: Peripheral blood stem cell transplantation procedures are used for people with sickle cell disease. Researchers want to improve the success and reduce the complications for these procedures.
- Trial name
- NCT03077542
- Testing
- haploidentical stem cell transplant, Sirolimus, Alemtuzumab
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome)
Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)
AlloHeme is a blood-based monitoring test developed by the CareDx laboratory that utilizes NGS technology coupled with a proprietary algorithm to predict the likelihood of a relapse in post-allo-HCT AML/MDS patients.
- Conditions
- AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome), CMML
- Trial name
- FORWARD (NCT07607327)
- Testing
- AlloHeme
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- CareDx
Kidney Failure, Kidney Transplant; Complications
Delayed Tolerance Through Mixed Chimerism
This study will examine the safety and effectiveness of a bone marrow transplant after kidney transplant (from either a living or deceased donor).
- Conditions
- Kidney Failure, Kidney Transplant; Complications, Chimera
- Trial name
- NCT05900401
- Testing
- Bone Marrow Transplant, Peripheral Blood Stem Cell Collection, Fludarabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital